| Detected | Trial | Change |
|---|---|---|
| 2026-06-11 | NCT05100862 A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants… |
Sponsor changed: BeiGene -> BeOne Medicines |
| 2026-06-09 | NCT06422520 A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in… |
Trial completed |
| 2026-06-09 | NCT06422520 A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in… |
Enrollment reduced: 120 -> 63 participants |
| 2026-06-09 | NCT06422520 A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in… |
date change Primary completion moved earlier: 2026-12-01 -> 2026-05-15 |
| 2026-06-09 | NCT06422520 A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in… |
date change Completion moved earlier: 2027-01-31 -> 2026-05-15 |
| 2026-06-05 | NCT06596473 A Study of BG-C477 in Participants With Advanced Solid Tumors |
Trial sites expanded: 49 -> 52 locations |
| 2026-06-04 | NCT07277231 A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With… |
Trial sites expanded: 46 -> 66 locations |
| 2026-06-04 | NCT07226349 A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced… |
Trial sites expanded: 18 -> 21 locations |
| 2026-06-04 | NCT06427941 A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without… |
Trial sites expanded: 29 -> 46 locations |
| 2026-06-04 | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With… |
Trial completed |
| 2026-06-04 | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With… |
date change Primary completion moved earlier: 2026-07 -> 2026-05-23 |
| 2026-06-04 | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With… |
date change Completion moved earlier: 2026-07 -> 2026-05-23 |
| 2026-06-04 | NCT06589596 An Investigational Study of BGB-58067 As a Single Agent and in Combination With… |
Trial sites expanded: 82 -> 87 locations |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
Trial terminated — check why_stopped for reason |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
critical why stopped: null → "The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape." |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
Enrollment reduced: 514 -> 47 participants |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
Sponsor changed: BeiGene -> BeOne Medicines |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
date change Primary completion moved earlier: 2026-12 -> 2026-04-23 |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
date change Completion moved earlier: 2026-12 -> 2026-04-23 |
| 2026-06-04 | NCT07492641 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… |
Trial sites expanded: 4 -> 13 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-05 | NCT07628881 A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral… | Phase 1 | Not Yet Recruiting |
| 2026-06-01 | NCT07619287 An Investigational Study of BG-75202 Alone and in Combination With Other Agents in… | Phase 1 | Not Yet Recruiting |
| 2026-05-15 | NCT07590102 A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor… | Phase 1 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06970743 | A Study of BGB-16673 Compared to Investigator's Choice in Participants With… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06846671 | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic… | CLL | Recruiting |
| NCT07043400 | A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus… | Metastatic Gastric Adenocarcinoma | Recruiting |
| NCT06742996 | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared… | Mantle Cell Lymphoma | Recruiting |
| NCT06973187 | A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT07277231 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT07492641 | BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… | HR+/HER2- Breast Cancer | Recruiting |
| NCT06943872 | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT05100862 | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants… | Relapsed/Refractory Follicular Lymphoma | Recruiting |
| NCT04002297 | A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With… | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | Active, Not Recruiting |
| NCT06073821 | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax… | CLL | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT05707377 | A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary… | Primary Membranous Nephropathy | Active, Not Recruiting |
| Phase 2 | |||
| NCT07554521 | A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally… | Advanced Unresectable Gastric Adenocarcinoma | Recruiting |
| NCT05952037 | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy… | Waldenstrom Macroglobulinemia | Active, Not Recruiting |
| NCT06637501 | A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT04973605 | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations… | Relapsed/Refractory Multiple Myeloma | Recruiting |
| NCT05006716 | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell… | B-cell Malignancy | Recruiting |
| NCT06634589 | A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other… | B-cell Malignancy | Recruiting |
| NCT06697184 | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating… | Chronic Lymphocytic Leukemia | Recruiting |
| Phase 1 | |||
| NCT07412691 | A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With… | Skin Diseases | Recruiting |
| NCT06803680 | A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor | Recruiting |
| NCT07181681 | A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents… | Solid Tumors | Recruiting |
| NCT06120283 | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer… | Advanced Solid Tumor | Recruiting |
| NCT06598800 | Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants… | Advanced Solid Tumor | Recruiting |
| NCT06625593 | A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b… | Advanced Solid Tumor | Recruiting |